PY
Therapeutic Areas
GAIA BioMedicine Pipeline
| Drug | Indication | Phase |
|---|---|---|
| GAIA-102 (fulamleucel) (iv) | Non-Small Cell Lung Cancer (NSCLC) | Early clinical trial |
| GAIA-102 (fulamleucel) (ip) | Gastric Cancer, Pancreatic Cancer | Early clinical trial |
| GAIA-102 (fulamleucel) (iv + pretreatment) | Neuroblastoma | Early clinical trial |
| GAIA-121 to -125 | Not Specified (GAAAP-targeted) | Preclinical |
| GAIA-202 | Not Specified (ES/iPS-derived) | Preclinical |
| GAIA-251 | Not Specified (ES/iPS-derived) | Preclinical |